It has been four years since this journey started, but (this chapter at least) has come to an end! Our work on "Chemical generation of checkpoint inhibitory T cell engagers for the treatment of cancer" is now online in @NatureChemistry!
https://t.co/jUd5EFBswL
1/9
Breaking news: Thousands of researchers and their supporters, including recently fired federal workers, have gathered across the U.S. in response to layoffs and funding cuts ordered by the Trump administration. https://t.co/RNz9it0uoD
The mood was defiant at many of the rallies, where chants of “Scientists will not be silenced”, “Facts over fear” and “What do we want? Peer review! When do we want it? Now!” were heard.
https://t.co/Ux1g91McIV
Excited to report that protocol for DNA-encoded, Liquid Glycan Array (LiGA) is out in @NatureProtocols. In addition to the protocol, we report how the expression level of Siglecs and cell types affect their ability to bind to LiGA.
https://t.co/sdcmpVj2FA
🚨PhD Opportunity:🚨
Come and join us and @VijayChudasama_ at UCL Chemistry investigating new chemical methods for empowering antibody conjugates partnered with @GSK! 🧪
See https://t.co/qiPX93pOmV for more info:
https://t.co/jul9fxS07u
#MeetTheResearcher
Introducing André Shamsabadi, PhD from the Stevens Group this week.
André is a Research Associate, working on design and application of novel nanoparticle-bioreceptor conjugates for ultra-sensitive biosensing. #KavliOxford
Excited to share our latest @NaturePortfolio@MethodsPrimers Primer of Top-down Proteomics. Here we discuss the underlying principles, recent advances, and present an outlook on the future. Beautiful PrimeView by Haley Wallen & Sam Whitham. Check it out!!👉https://t.co/r7YugfjrLS
Very proud to share our latest collaborative paper with @BakerGroupUCL where we disclose the chemo- and regio-selective differential modification of cysteines on a native antibody; a first-in-class strategy! Led by the fantastic @yapyongyi! @UCLChemistry
https://t.co/ssC308zyk1
It has been four years since this journey started, but (this chapter at least) has come to an end! Our work on "Chemical generation of checkpoint inhibitory T cell engagers for the treatment of cancer" is now online in @NatureChemistry!
https://t.co/jUd5EFBswL
1/9
We conclude that detailed biological testing is needed to investigate the sialidase-containing CiTE.
Well, here is a pre-print by the @pengwuTSRI group, where they test their own BiTE-sialidase fusion just so. I am excited to see the final version!
7/9
https://t.co/Y35dmZyZZy
1/7 Our work online today, showing that targeted desialylation enhances the efficacy of bispecific T-cell engager (BiTE) for treating solid tumors #glycotime https://t.co/LRW3YCkKUu
Antibody drug conjugates (ADCs) are all the rage, for good reason.
They're generating stellar efficacy results in clinic, though they're not perfect.
I looked through 40+ ADC companies founded after 2010 to see what each was trying to improve on and with what new approach. ⬇️
Glad to see our work on Genetically Encoded LYTACs (GELYTACs) in @PNASNews. Highlights include directed evolution of GELYTACs & secretion of GELYTACs by primary T-cells. Special thanks to @aliceyting@CarolynBertozzi, and collaborators @mackalllab. https://t.co/Yqf05BFebu
New review from Lina Petersone & I highlights recent findings on IL-21 and germinal center biology. Such an interesting cytokine!
https://t.co/2dWdEak4f3
Our new review on the Immunology of #Type1Diabetes now out in @NatRevImmunol – really important area for understanding and maximising immunotherapies. Kevan Herold @Bruskolab Thomas Delong, Ana Luisa Perdigoto, Noah Biru @DUK_research @JDRFUK @iit_ucl
https://t.co/8VJXdTZcUw
Thrilled to share my first preprint! TICTACs highlight the modularity of antibody-carbohydrate conjugates and their potential to act as highly tumor-specific immunotherapies. Shoutout to my collaborator Nick Till, and thank you Carolyn for your support!